Figure 1.

All-cause medical, outpatient pharmacy, and total costs for patients with ADPKD compared with non-ADPKD matched-control^a patients during the 6-month observation period (presented by CKD disease stage, in 2010 US dollars). ^aADPKD patients were grouped by CKD stage and matched by age and sex to a control population without ADPKD. Less than 1.0% of all non-ADPKD matched control patients had a diagnosis for CKD, procedure for dialysis, or an indicator for post-transplant. Plot illustrates the contrast in costs between ADPKD patients and matched controls. Additionally, increasing costs are observed with worsening CKD stage.

Abbreviations: ADPKD, autosomal dominant polycystic kidney disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate.